The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies

Headache - Tập 55 Số 1 - Trang 3-20 - 2015
Michael J. Marmura1, Stephen D. Silberstein2, Todd J. Schwedt1
1Department of Neurology, Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA
2Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA

Tóm tắt

The study aims to provide an updated assessment of the evidence for individual pharmacological therapies for acute migraine treatment. Pharmacological therapy is frequently required for acutely treating migraine attacks. The American Academy of Neurology Guidelines published in 2000 summarized the available evidence relating to the efficacy of acute migraine medications. This review, conducted by the members of the Guidelines Section of the American Headache Society, is an updated assessment of evidence for the migraine acute medications. A standardized literature search was performed to identify articles related to acute migraine treatment that were published between 1998 and 2013. The American Academy of Neurology Guidelines Development procedures were followed. Two authors reviewed each abstract resulting from the search and determined whether the full manuscript qualified for review. Two reviewers studied each qualifying full manuscript for its level of evidence. Level A evidence requires at least 2 Class I studies, and Level B evidence requires 1 Class I or 2 Class II studies. The specific medications – triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan [oral, nasal spray, injectable, transcutaneous patch], zolmitriptan [oral and nasal spray]) and dihydroergotamine (nasal spray, inhaler) are effective (Level A). Ergotamine and other forms of dihydroergotamine are probably effective (Level B). Effective nonspecific medications include acetaminophen, nonsteroidal anti‐inflammatory drugs (aspirin, diclofenac, ibuprofen, and naproxen), opioids (butorphanol nasal spray), sumatriptan/naproxen, and the combination of acetaminophen/aspirin/caffeine (Level A). Ketoprofen, intravenous and intramuscular ketorolac, flurbiprofen, intravenous magnesium (in migraine with aura), and the combination of isometheptene compounds, codeine/acetaminophen and tramadol/acetaminophen are probably effective (Level B). The antiemetics prochlorperazine, droperidol, chlorpromazine, and metoclopramide are probably effective (Level B). There is inadequate evidence for butalbital and butalbital combinations, phenazone, intravenous tramadol, methadone, butorphanol or meperidine injections, intranasal lidocaine, and corticosteroids, including dexamethasone (Level C). Octreotide is probably not effective (Level B). There is inadequate evidence to refute the efficacy of ketorolac nasal spray, intravenous acetaminophen, chlorpromazine injection, and intravenous granisetron (Level C). There are many acute migraine treatments for which evidence supports efficacy. Clinicians must consider medication efficacy, potential side effects, and potential medication‐related adverse events when prescribing acute medications for migraine. Although opioids, such as butorphanol, codeine/acetaminophen, and tramadol/acetaminophen, are probably effective, they are not recommended for regular use.

Từ khóa


Tài liệu tham khảo

10.1001/jama.1992.03480010072027

Headache Classification of the International Headache Society, 2013, The International Classification of Headache Disorders, 3rd edition (beta version), Cephalalgia, 33, 627

10.1212/WNL.0b013e3182535d0c

10.1212/WNL.55.6.754

10.1177/0333102411417901

American Academy of Neurology, 2011, Clinical Practice Guideline Process Manual

Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011, Clinical Practice Guidelines We Can Trust

10.1212/WNL.57.10.1811

10.1046/j.1468-2982.2000.00091.x

10.1111/j.1468-2982.2008.01546.x

10.1111/j.1526-4610.2006.00686.x

10.1111/j.1526-4610.2005.05151.x

10.1046/j.1468-2982.2002.00372.x

10.1046/j.1526-4610.2003.03043.x

10.1046/j.1468-2982.2002.00300.x

10.1111/j.1468-2982.2005.00981.x

10.1046/j.1468-2982.2003.00554.x

10.1111/j.1468-1331.2004.00914.x

10.1046/j.1526-4610.42.s2.5.x

10.1046/j.1526-4610.2002.02012.x

10.1185/030079904X2745

10.1111/j.1468-1331.2005.01076.x

10.1046/j.1468-2982.1999.019005525.x

10.1111/j.1526-4610.2006.00466.x

10.1111/j.1468-2982.2007.01313.x

10.1111/j.1526-4610.2011.02027.x

10.1177/0333102410390399

10.1016/S0149-2918(04)90020-3

10.1016/j.clinthera.2005.04.003

10.1016/j.clinthera.2006.03.013

10.1111/j.1526-4610.2012.02198.x

10.1177/0333102409359314

10.1001/jama.297.13.1443

10.1111/j.1526-4610.2009.01458.x

10.1185/030079905X28926

10.2165/00023210-200418150-00007

10.2165/00023210-200519020-00003

10.1111/j.1526-4610.2005.05004.x

10.1111/j.1526-4610.2009.01453.x

10.1111/j.1526-4610.2011.01869.x

10.1046/j.1468-2982.1983.0302129.x

10.1046/j.1526-4610.1997.3701012.x

10.1001/archinte.160.22.3486

10.1016/j.pain.2005.07.002

10.1016/S0736-4679(02)00502-4

10.1212/01.WNL.0000042477.63516.B2

10.1111/j.1468-2982.2004.00764.x

10.1046/j.1526-4610.2002.02076.x

10.1111/j.1526-4610.2005.05065.x

10.1046/j.1468-2982.1993.1302117.x

10.1046/j.1468-2982.1991.1102059.x

10.1046/j.1468-2982.1999.019004232.x

10.1111/j.1468-2982.2007.01236.x

10.1111/j.1468-2982.2005.01064.x

10.1177/0333102410367523

10.1046/j.1526-4610.2001.041007665.x

10.1177/0333102412451359

10.1111/j.1526-4610.2005.00264.x

10.1016/j.clinthera.2007.07.017

10.1111/j.1468-2982.2004.00807.x

10.1046/j.1468-2982.2002.00364.x

10.1111/j.1468-2982.2004.00840.x

10.1111/j.1526-4610.2004.04010.x

Waberzinek G, 2007, Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine, Neuro Endocrinol Lett, 28, 59

10.1212/01.WNL.0000147332.41993.90

10.1111/j.1526-4610.2006.00313.x

Thông tin
Thông tin xuất bản

Headache

Tập 55 Số 1

3-20

Thông tin tác giả